Fiduciary Trust Co. Increases Position in Becton, Dickinson and Company (NYSE:BDX)

Fiduciary Trust Co. boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 13.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 80,345 shares of the medical instruments supplier’s stock after buying an additional 9,489 shares during the period. Fiduciary Trust Co.’s holdings in Becton, Dickinson and were worth $14,739,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Macquarie Group Ltd. raised its stake in shares of Becton, Dickinson and by 16.0% in the fourth quarter. Macquarie Group Ltd. now owns 67,709 shares of the medical instruments supplier’s stock valued at $11,209,000 after buying an additional 9,340 shares during the last quarter. First National Bank of Omaha raised its stake in shares of Becton, Dickinson and by 6.7% in the first quarter. First National Bank of Omaha now owns 20,960 shares of the medical instruments supplier’s stock valued at $3,845,000 after buying an additional 1,310 shares during the last quarter. TNB Financial purchased a new stake in shares of Becton, Dickinson and during the first quarter valued at about $587,000. Oakmont Partners LLC purchased a new stake in shares of Becton, Dickinson and during the first quarter valued at about $920,000. Finally, Private Trust Co. NA raised its stake in shares of Becton, Dickinson and by 154.8% in the first quarter. Private Trust Co. NA now owns 4,196 shares of the medical instruments supplier’s stock valued at $769,000 after buying an additional 2,549 shares during the last quarter. Hedge funds and other institutional investors own 75.71% of the company’s stock.

Becton, Dickinson and Company (NYSE BDX) traded up 1.08% during trading on Friday, reaching $200.36. The company had a trading volume of 1,251,199 shares. The firm has a market capitalization of $45.59 billion, a P/E ratio of 58.02 and a beta of 1.05. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63. The firm’s 50-day moving average price is $198.90 and its 200 day moving average price is $187.70.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. During the same period last year, the firm earned $2.35 EPS. Becton, Dickinson and’s revenue for the quarter was down 5.1% compared to the same quarter last year. Equities analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.46%. Becton, Dickinson and’s dividend payout ratio is currently 83.43%.

TRADEMARK VIOLATION WARNING: “Fiduciary Trust Co. Increases Position in Becton, Dickinson and Company (NYSE:BDX)” was reported by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.thestockobserver.com/2017/08/12/fiduciary-trust-co-increases-position-in-becton-dickinson-and-company-nysebdx.html.

BDX has been the topic of several research reports. Evercore ISI upgraded Becton, Dickinson and from an “in-line” rating to an “outperform” rating and boosted their target price for the company from $186.00 to $200.00 in a research note on Monday, April 24th. Zacks Investment Research lowered Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, May 4th. Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and lowered their target price for the company from $210.00 to $180.00 in a research note on Friday, June 30th. Cowen and Company restated an “outperform” rating and issued a $230.00 target price (up from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. Finally, BidaskClub upgraded Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $195.79.

In other Becton, Dickinson and news, VP Jeffrey S. Sherman sold 28,765 shares of the firm’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the sale, the vice president now directly owns 70,821 shares of the company’s stock, valued at $13,171,289.58. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Ellen R. Strahlman sold 9,283 shares of the firm’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the sale, the insider now directly owns 26,638 shares in the company, valued at $5,279,917.98. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 44,019 shares of company stock worth $8,368,433. 1.40% of the stock is owned by insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply